All In Biotech

NDA 021436 · Otsuka

Abilify

Aripiprazole · Oral · Atypical Antipsychotic

NovelOrphan

Last checked: Nov 21, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Nov 15, 2002

Approved uses

13

Original approval plus efficacy supplements

Registered trials

401

123 Phase 3, 18 recruiting

FAERS reports

117,169

79,602 serious, 6,592 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24 years; there was a reduction in risk with antidepressant use in patients aged 65 years and older [see Warnings and Precautions (5.3) ] . In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for...

What it is approved for

From the label in effect Jan 29, 2025.

ABILIFY (aripiprazole) Tablets are indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette's Disorder ABILIFY is an atypical antipsychotic. ABILIFY is indicated for: Schizophrenia ( 14.1 ) Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder ( 14.2 ) Adjunctive Treatment of Major Depressive Disorder ( 14.3 ) Irritability Associated with Autistic Disorder ( 14.4 ) Treatment of Tourette's Disorder ( 14.5 )

Mechanism: The mechanism of action of aripiprazole in schizophrenia or bipolar mania, is unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • ABILIFY · ARIPIPRAZOLE 2MG · TABLET, ORAL · Prescription · TE AB
  • ABILIFY · ARIPIPRAZOLE 30MG · TABLET, ORAL · Prescription · TE AB
  • ABILIFY · ARIPIPRAZOLE 15MG · TABLET, ORAL · Prescription · TE AB
  • ABILIFY · ARIPIPRAZOLE 5MG · TABLET, ORAL · Prescription · TE AB
  • ABILIFY · ARIPIPRAZOLE 20MG · TABLET, ORAL · Prescription · TE AB
  • ABILIFY · ARIPIPRAZOLE 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Aripiprazole" as an intervention, any sponsor and status, largest first.

All 401 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective8,220
  • weight increased7,537
  • off label use7,367
  • anxiety5,051
  • product use in unapproved indication4,908
  • fatigue4,193
  • suicidal ideation4,038
  • nausea4,005
  • depression3,968
  • insomnia3,832
  • drug interaction3,695
  • tremor3,625

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,521
20051,783
2006927
20071,986
20081,061
20096,101
20102,518
20114,124
20124,193
20133,267
20146,448
20157,439
20167,002
201712,295
20189,454
20196,382
20206,054
20216,740
20225,661
20235,988
20246,012
20255,563
20264,646

Recalls

5 FDA enforcement reports for this application.

  • Apr 9, 2024 · Class III · Ongoing

    Cross Contamination with Other Products

  • Apr 9, 2024 · Class III · Ongoing

    Cross Contamination with Other Products

  • Apr 9, 2024 · Class III · Ongoing

    Cross Contamination with Other Products

  • Apr 9, 2024 · Class III · Ongoing

    Cross Contamination with Other Products

  • Nov 2, 2012 · Class II · Terminated

    CGMP Deviations: A drum of Abilify 30 mg Tablets rejected during the compression stage was not segregated from the other portion of the lot and was inadvertently shipped, packaged and distributed.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Abilify (Aripiprazole)

2024 spending

$7.1M

Beneficiaries

1,480

7,139 claims

Per beneficiary

$4,781

$22.53 per unit

View as table
YearSpending
2020$24,481,911
2021$20,484,851
2022$13,141,218
2023$11,882,943
2024$7,075,288

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,036 on PubMed

Sponsor: Otsuka

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.